Canine

Dog health innovation is maturing fast, but Europe's insurance and vet access patterns look nothing like the US market it's often built for.

Discovery: is genetic testing's next step understanding risk, or acting on it early? Is the bigger scientific gap a specific disease, or ageing and prevention broadly?
Development: what's slowing US built innovations adapting to European access and payment patterns? What's the barrier to affordability for everyday use?
Delivery: what does lower European insurance uptake mean for pricing and positioning? What would make preventive care the norm, not the exception?